Anti-Siglec-3/CD33 Antibody (LintuzumAb)
Catalog No.
F1168
Anti-Siglec-3/CD33 Antibody (LintuzumAb)
Featured Products
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces TNFα-induced proinflammatory cytokine and chemokine production by AML cells. Lintuzumab exerts tumor cell killing effects on MDR? and MDR+ AML cell lines and primary AML patient samples through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities. Lintuzumab improves the survival rate of tumor-bearing mice and reduces tumor burden.
Quality Control & DataSheet
- View current batch:
-
Purity > 90% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
145 kDa
Dry ice
166089-32-3
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
SGN-33, HuM195, Actimab-A
100 mM Pro 20 mM Arg pH 5.0. No preservative!
O14793
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
GDF8 / Myostatin
Please avoid freeze-thaw cycles.